默沙东新冠药：莫诺拉韦 molnupiravir

Drug Class

Nucleoside antiviral agent

Mechanism

Metabolized to a cytidine analog that is incorporated into viral RNA by viral RNA polymerase, causing lethal mutations during viral replication.

Approved Indication

FDA EUA authorized for the treatment of mild-to-moderate COVID-19 in adults at high risk for progression to severe disease, for whom alternative treatments are not accessible.

What This Means For Patients

默沙东新冠药：莫诺拉韦 is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Emergency use authorization (2021) — Sources

Pivotal Clinical Evidence

• MOVe-OUT — Jayk Bernal et al., N Engl J Med 2022 (NCT04575597) — Sources

Sources

• https://www.fda.gov/media/155054/download
• https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/ggtg/qtgg/20221230210006199.html